Sylatron: A pegylated interferon for use in melanoma;Sylatron: Une formulation pégylée d'interféron pour le traitement du mélanome

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 830-838

  Patel, Jai N ^a   Walko Dr , Christine M ^b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Melanoma; Peginterferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAFFEINE; DAPSONE; DEXTROMETHORPHAN; MIDAZOLAM; PEGINTERFERON ALPHA2B; TOLBUTAMIDE;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CHILL; DEPRESSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSGEUSIA; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; KIDNEY CLEARANCE; MELANOMA; MYALGIA; NAUSEA; OLFACTORY NERVE DISEASE; OVERALL SURVIVAL; PARESTHESIA; PATIENT COUNSELING; PLASMA HALF LIFE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEROCONVERSION; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMATIC REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; MELANOMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84862246130     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q791     Document Type: Article

References (27)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.DOI 10.1200/JCO.2009.23.4799.
2. American Cancer Society. Melanoma skin cancer. www.cancer/org/Cancer/SkinCancer-Melanoma/DetailedGuide/index (accessed 2011 Nov 01).
3. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7.DOI 10.1200/JCO.2004.11.044.
4. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-8.DOI 10.1158/1078-0432.CCR-08-0116.
5. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as secondline therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13:531-6.
6. Yoon C, Papadopoulos NE, Camacho LH, et al. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res 2010;20:43-7.
7. Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 2011;45:510-9.DOI 10.1345/aph.1P651.
8. Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 2011;45:1399-405.DOI 10.1345/aph.1Q363.
9. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
10. Okuyama S, Gonzalez R, Lewis KD. Pegylated interferon alpha-2b as adjuvant treatment of stage III malignant melanoma: an evidence-based review. Core Evid 2010;5:39-48.
11. Agarwala SS, Lee SJ, Flaherty LE, et al. Randomized phase III trial of high-dose interferon alfa-2b for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) (abstract 8505). J Clin Oncol 2011;29.
12. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002;20:3841-9.DOI 10.1200/JCO.2002.02.051.
13. Nathanson KL. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 1976;44:67-76.
14. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-55.DOI 10.1200/JCO.2007.14.6423.
15. Daud AI, Xu C, Hwu WJ, et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2011;67:657-66.DOI 10.1007/s00280-010-1326-9.
16. Product information. Sylatron (pegylated interferon alfa-2b). Kenilworth, NJ: Schering Corp., March 2011.
17. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-26.DOI 10.1016/s0140-6736(08)61033-8.
18. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27:2916-23.DOI 10.1200/JCO.2008.20.2069.
19. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
20. Bouwhuis MG, Suciu S, Testori A, et al. Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 2010;28:2460-6.DOI 10.1200/JCO.2009.24.6264.
21. Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol 2011;67:591-9.DOI 10.1007/s00228-010-0972-5.
22. Islam M, Frye RF, Richards TJ, et al. Differential effect of IFN alpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002;8:2480-7.
23. Friebe A, Horn M, Schmidt F, et al. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 2010;51:466-73.DOI 10.1176/appi.psy.51.6.466.
24. Kaehler KC, Sondak VK, Schadendorf D, Hauschild A. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer 2010;46:41-6.DOI 10.1016/j.ejca.2009.10.004.
25. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 2004;22:569-80.
26. Cormier JN, Xing Y, Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 2007;25:2442-8.DOI 10.1200/JCO.2007.10.7284.
27. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006;94:492-8.DOI 10.1038/sj.bjc.6602973